Total amount: € 0,00
Fabbrocini G., Panariello L., Russo G., Romano M. C.
Clinica Dermatologica, Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, Napoli, Italia
AIM: Skin and cutaneous annexes represent main toxicity targets of new chemotherapy agents, called targeted drugs. Among these drugs, epidermal growth factor receptor inhibitors (EGFRi) are widely used. This drug can cause new toxicities like papulo-pustular rash, hand foot syndrome, paronychia and periungueal granulomas. The aim of our study is to evaluate the effectiveness and tolerability of a silk-fibroin fabric (Dermasilk®) treated with a water-resistant antimicrobial finish in patients undergoing chemotherapy.
METHODS: We selected 60 patients of both sexes, aged between 18 and 70 years, suffering from EGFRi-induced cutaneous reactions. Patients were divided in 3 groups, each one composed of 20 subjects: Group A composed of patients affected by hand foot syndrome, Group B composed of patients affected by papulo-pustular rash, Group C composed of patients wearing a wig for chemotherapy-induced alopecia. Each group was divided in two subgroups: subgroup 1 and subgroup 2. Patients of subgroup 1 received pharmacological and dermocosmetological therapy usually prescribed to treat the specific side effect, and they were also asked to use Dermasilk® clothing. Patients of subgroup 2 received only the prescribed pharmacological and dermocosmetological therapy. The association of pharmacological and dermocosmetological therapy with Dermasilk® clothing induced: a reduction of erythema, evaluated through both digital images and clinical scale; an increase of skin brightness, evaluated through colorimetry; a reduction of TEWL, evaluated through Tewameter; an excellent tolerability, evaluated through a specific questionnaire.
RESULTS: The results obtained in subgroup 1 were better than those obtained in subgroup 2.
CONCLUSION: We can conclude that Dermasilk® clothing may be a useful adjuvant tool for the management of chemotherapy adverse skin reactions, allowing oncological patients to achieve better and faster results compared to pharmacological and dermocosmetological therapy alone.